NO20002587D0 - FremgangsmÕter for behandling av postmenopause-kvinner ved bruk av ultra-lave doser av østrogen - Google Patents

FremgangsmÕter for behandling av postmenopause-kvinner ved bruk av ultra-lave doser av østrogen

Info

Publication number
NO20002587D0
NO20002587D0 NO20002587A NO20002587A NO20002587D0 NO 20002587 D0 NO20002587 D0 NO 20002587D0 NO 20002587 A NO20002587 A NO 20002587A NO 20002587 A NO20002587 A NO 20002587A NO 20002587 D0 NO20002587 D0 NO 20002587D0
Authority
NO
Norway
Prior art keywords
estrogen
ultra
procedures
treatment
low doses
Prior art date
Application number
NO20002587A
Other languages
English (en)
Other versions
NO20002587L (no
NO326929B1 (no
Inventor
Steven Cummins
Herman Ellman
Bruce Ettinger
Original Assignee
Univ California
Kaiser Foundation Health Plan
Permanente Medical Group
Berlex Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25523181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20002587(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California, Kaiser Foundation Health Plan, Permanente Medical Group, Berlex Lab filed Critical Univ California
Publication of NO20002587D0 publication Critical patent/NO20002587D0/no
Publication of NO20002587L publication Critical patent/NO20002587L/no
Publication of NO326929B1 publication Critical patent/NO326929B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
NO20002587A 1997-11-21 2000-05-19 Anvendelse av ostrogen for fremstilling av et medikament, samt et sett. NO326929B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/975,599 US5891868A (en) 1997-11-21 1997-11-21 Methods for treating postmenopausal women using ultra-low doses of estrogen
PCT/US1998/024677 WO1999026631A1 (en) 1997-11-21 1998-11-19 Methods for treating postmenopausal women using ultra-low doses of estrogen

Publications (3)

Publication Number Publication Date
NO20002587D0 true NO20002587D0 (no) 2000-05-19
NO20002587L NO20002587L (no) 2000-07-19
NO326929B1 NO326929B1 (no) 2009-03-16

Family

ID=25523181

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002587A NO326929B1 (no) 1997-11-21 2000-05-19 Anvendelse av ostrogen for fremstilling av et medikament, samt et sett.

Country Status (25)

Country Link
US (1) US5891868A (no)
EP (2) EP1032398B1 (no)
JP (2) JP2001523722A (no)
KR (1) KR100576568B1 (no)
CN (1) CN100398110C (no)
AT (2) ATE383862T1 (no)
AU (1) AU760108B2 (no)
BR (1) BR9814984A (no)
CA (1) CA2306881C (no)
CL (1) CL2004001852A1 (no)
CZ (1) CZ299226B6 (no)
DE (2) DE69829501T2 (no)
EA (1) EA004573B1 (no)
EE (1) EE04221B1 (no)
ES (2) ES2299912T3 (no)
HU (1) HUP0004339A3 (no)
IL (1) IL136175A (no)
IS (1) IS2132B (no)
NO (1) NO326929B1 (no)
NZ (1) NZ504668A (no)
PL (1) PL193897B1 (no)
PT (1) PT1032398E (no)
SK (1) SK284971B6 (no)
TR (1) TR200001460T2 (no)
WO (1) WO1999026631A1 (no)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6692763B1 (en) * 1998-11-19 2004-02-17 The Regents Of The University Of California Methods for treating postmenopausal women using ultra-low doses of estrogen
US5891868A (en) * 1997-11-21 1999-04-06 Kaiser Foundation Health Plan, Inc. Methods for treating postmenopausal women using ultra-low doses of estrogen
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
EP1248626B1 (en) * 2000-01-14 2006-07-05 Sterix Limited Pharmaceutical compositions containing steroidal structures and uses thereof
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US20050113351A1 (en) * 2000-03-21 2005-05-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20040176336A1 (en) * 2000-03-21 2004-09-09 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
DE60120458T2 (de) * 2000-10-13 2007-01-11 Abbott Laboratories, Abbott Park Verfahren zur bestimmung der anfangsdosis von vitamin d verbindungen
CA2448235A1 (en) 2001-07-31 2003-02-13 Pfizer Products Inc. Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
WO2005011617A2 (en) * 2003-07-31 2005-02-10 Ivax Corporation Transmucosal dosage forms for brain-targeted steroid chemical delivery systems
US7685012B2 (en) * 2003-12-30 2010-03-23 Wilson Thomas W Method and system for analyzing resource allocation based on cohort times
US20060040904A1 (en) * 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
US8022053B2 (en) * 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
US20060183724A1 (en) * 2005-02-03 2006-08-17 Diliberti Charles E Compositions of unconjugated estrogens and methods for their use
US8834862B2 (en) * 2005-04-19 2014-09-16 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
US8217024B2 (en) * 2005-12-27 2012-07-10 Teva Women's Health, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
US20070254036A1 (en) 2006-04-13 2007-11-01 Besins Healthcare Sa Treatment of menopause associated symptoms
NZ584190A (en) * 2007-10-15 2012-09-28 Alza Corp Once-a-day replacement transdermal administration of fentanyl
US20090110656A1 (en) * 2007-10-31 2009-04-30 Lemke Sarah A Skin cooling composition
US20090157153A1 (en) * 2007-12-13 2009-06-18 Sarah Anne Lemke Skin cooling system
DE102009007771B4 (de) 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Bukkales Applikationssystem, 17α-Estradiol enthaltend
ES2533584T3 (es) * 2010-04-15 2015-04-13 Bayer Intellectual Property Gmbh Formas de dosificación oral sólidas de dosis baja para TSH
HUP1000335A2 (en) * 2010-06-22 2012-02-28 Avidin Kft Use of an estrogen derivative for the treatment and/or prevention of psychiatric conditions
RU2456955C1 (ru) * 2011-03-01 2012-07-27 Государственное образовательное учреждение высшего профессионального образования "Алтайский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ ортопедического лечения женщин постменопаузального периода съемными пластиночными протезами
CN102397550B (zh) * 2011-08-30 2013-05-08 广东医学院 一组由阿司匹林与雌激素组成的防治骨质疏松症的药物组合物
JP2013097693A (ja) * 2011-11-04 2013-05-20 Hitachi Solutions Ltd 骨粗鬆症リスク判定システム及びプログラム
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP3054934B1 (en) * 2013-10-07 2024-05-22 Teikoku Pharma USA, Inc. Methods and compositions for treating withdrawal syndromes using non-sedative dexmedetomidine transdermal compositions
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4722941A (en) * 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4460372A (en) * 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4573996A (en) * 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
US4624665A (en) * 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US5188835A (en) * 1986-06-16 1993-02-23 Kabi Pharmacia Ab Intravaginal devices
SE8602666D0 (sv) * 1986-06-16 1986-06-16 Leo Ab Intravaginal devices
US5223261A (en) * 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
JP2960832B2 (ja) * 1992-05-08 1999-10-12 ペルマテック テクノロジー アクチェンゲゼルシャフト エストラジオールの投与システム
US5460820B1 (en) * 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
US5891868A (en) * 1997-11-21 1999-04-06 Kaiser Foundation Health Plan, Inc. Methods for treating postmenopausal women using ultra-low doses of estrogen

Also Published As

Publication number Publication date
HUP0004339A2 (hu) 2001-05-28
EA200000563A1 (ru) 2001-08-27
HK1082919A1 (en) 2006-06-23
CN100398110C (zh) 2008-07-02
WO1999026631A1 (en) 1999-06-03
TR200001460T2 (tr) 2000-11-21
IS5468A (is) 2000-04-26
AU760108B2 (en) 2003-05-08
CN1279611A (zh) 2001-01-10
DE69829501D1 (de) 2005-04-28
JP2001523722A (ja) 2001-11-27
BR9814984A (pt) 2000-10-03
IL136175A0 (en) 2001-05-20
NO20002587L (no) 2000-07-19
EP1570848A1 (en) 2005-09-07
NZ504668A (en) 2002-11-26
CA2306881A1 (en) 1999-06-03
ATE291430T1 (de) 2005-04-15
EP1032398A1 (en) 2000-09-06
PL193897B1 (pl) 2007-03-30
DE69839026T2 (de) 2009-01-08
ES2299912T3 (es) 2008-06-01
CZ299226B6 (cs) 2008-05-21
EE200000307A (et) 2001-10-15
ATE383862T1 (de) 2008-02-15
KR100576568B1 (ko) 2006-05-08
DE69829501T2 (de) 2006-01-26
EE04221B1 (et) 2004-02-16
HUP0004339A3 (en) 2001-09-28
NO326929B1 (no) 2009-03-16
CZ20001602A3 (cs) 2001-02-14
JP2004083599A (ja) 2004-03-18
DE69839026D1 (de) 2008-03-06
EP1570848B1 (en) 2008-01-16
CL2004001852A1 (es) 2005-06-03
KR20010032257A (ko) 2001-04-16
ES2241188T3 (es) 2005-10-16
IS2132B (is) 2006-08-15
IL136175A (en) 2005-11-20
EA004573B1 (ru) 2004-06-24
PL341112A1 (en) 2001-03-26
US5891868A (en) 1999-04-06
AU1591499A (en) 1999-06-15
CA2306881C (en) 2008-09-02
SK7332000A3 (en) 2001-03-12
SK284971B6 (sk) 2006-03-02
PT1032398E (pt) 2005-08-31
EP1032398B1 (en) 2005-03-23

Similar Documents

Publication Publication Date Title
NO20002587L (no) FremgangsmÕter for behandling av postmenopausale-kvinner ved bruk av ultra-lave doser av østrogen
ZA9711353B (en) Intramedullary cavity nail for the treatment of fractures of the hip.
DE59812897D1 (de) Vorrichtung zum behandeln von malignen, tumorösen gewebebereichen
EP0961613A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF BONE RESORPTION DISORDERS, INCLUDING OSTEOPOROSIS
DE60022692D1 (de) (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
HUT67945A (en) Parathyroid hormon and raloxifene for increasing bone mass
ITMI951160A0 (it) Chiodo endomidollare bloccato adatto in particolare per le fratture del femore
EP0675723A4 (en) THERAPY USING BISPHOSPHONATES AND STROGENS TO TREAT AND PREVENT BONE RESORPTION.
DE69532804D1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
MXPA03005742A (es) Combinacion de un estrogeno y un androgeno para tratar deficiencias hormonales en mujeres que sufren terapia de reemplazo de estrogenos.
DE69509843D1 (de) Apparat zur Behandlung z.B. von Poststücken
NO20024735D0 (no) Anvendelse av fulvestrant for behandling av resistent brystcancer
TR200200278T2 (tr) Kalsilitik bileşimler
GB9916729D0 (en) Fuller for the treatment of leather,pelts and the like
DE60007178D1 (de) Verfahren und vorrichtung zur zerkleinerung und desinfektion von medizinischen abfällen
BR9704615A (pt) formononetina de metal alcalino e processo de estimulação micorrizal
DE69928501D1 (de) Mittel zur vorbeugung/behandlung von osteoporose
RU95100742A (ru) Способ удлинения костей
EP1156292A3 (en) Device for treatment of biological waste
MD1270F1 (en) Method for treatment of the hand navicular bone pseudarthrosis
AU1275400A (en) Method and apparatus for treating contaminated waste
DE69830811D1 (de) Verwendung von Oxazolidinonderivaten zur Behandlung von Psoriasis
ATA144696A (de) Vorrichtung zur behandlung von schenkenhalsfrakturen
UA34375A (uk) Спосіб лікування рака молочної залози
DE69828553D1 (de) Gerät zur behandlung von harnwegs- und anderen körperstenosen

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees